## Vasileios F Panoulas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7130824/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid Classification and Treatment Algorithm of Cardiogenic Shock Complicating Acute Coronary Syndromes: The SAVE ACS Classification. Journal of Interventional Cardiology, 2022, 2022, 1-10.	1.2	4
2	Successful percutaneous closure of aortic root-to-right ventricle fistula after transcatheter aortic valve implantation: a valuable option in high-risk surgical patients. European Heart Journal - Case Reports, 2022, 6, ytac094.	0.6	4
3	Prognostic Significance of Ventricular Arrhythmias in 13Â444 Patients With Acute Coronary Syndrome: A Retrospective Cohort Study Based on Routine Clinical Data (NIHR Health Informatics Collaborative) Tj ETQq1 1	0 <i>3</i> .84314	1 r <b>g</b> BT /Over
4	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. PLoS Medicine, 2022, 19, e1003911.	8.4	21
5	Implications of elevated troponin on time-to-surgery in non-ST elevation myocardial infarction (NIHR) Tj ETQq1 1	0.784314 1.7	rgBT /Over
6	Midâ€ŧerm clinical outcomes from use of Sirolimus coated balloon in coronary intervention; data from real world population. Catheterization and Cardiovascular Interventions, 2021, 98, 57-65.	1.7	10
7	Impact of Early (â‰ <b>2</b> 4Âh) Versus Delayed (>24Âh) Intervention in Patients With Non-ST Segment Elevation Myocardial Infarction: An Observational Study of 20,882 Patients From the London Heart Attack Group. Cardiovascular Revascularization Medicine, 2021, 22, 3-7.	0.8	5
8	A detailed explantation assessment protocol for patients with left ventricular assist devices with myocardial recovery. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 298-305.	1.1	8
9	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WINâ€TAVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 97, 516-526.	1.7	17
10	Outcomes of heart transplantation in patients bridged with Impella 5.0: Comparison with native chest transplanted patients without preoperative mechanical circulatory support. Artificial Organs, 2021, 45, 254-262.	1.9	8
11	Use of Impella RP for Acute Right Ventricular Failure Post-Pericardiectomy. Cardiovascular Revascularization Medicine, 2021, 28, 176-179.	0.8	2
12	Is the quality-of-life improvement after transcatheter aortic valve implantation equivalent to that achieved by surgical aortic valve replacement?. Interactive Cardiovascular and Thoracic Surgery, 2021, , .	1.1	0
13	The Role of Mechanical Circulatory Support in Patients With Severe Left Ventricular Impairment Treated With Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine, 2021, 28, 169-175.	0.8	5
14	Diagnosing STEMI in the presence of paced rhythm: dispelling the myth of the â€~uninterpretable paced ECG'. BMJ Case Reports, 2021, 14, e242546.	0.5	0
15	Predictors of Short-term Survival in Cardiogenic Shock Patients Requiring Left Ventricular Support Using the Impella CP or 5.0. CJC Open, 2021, 3, 1002-1009.	1.5	3
16	Impella as unloading strategy during VA-ECMO: systematic review and meta-analysis. Reviews in Cardiovascular Medicine, 2021, 22, 1503.	1.4	23
17	Using base excess, albumin, lactate and renal function to predict 30-day mortality in patients requiring impella monotherapy for left-sided mechanical circulatory support: The BALLAR score. Cardiovascular Revascularization Medicine, 2021, , .	0.8	3
18	Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry. Journal of Thrombosis and Thrombolysis, 2020, 50, 82-89.	2.1	21

#	Article	IF	CITATIONS
19	Clinical Indications of IMPELLA Short-Term Mechanical Circulatory Support in a Tertiary Centre. Cardiovascular Revascularization Medicine, 2020, 21, 629-637.	0.8	18
20	Initial experience of a selfâ€expanding transcatheter aortic valve with an outer pericardial wrap: The United Kingdom and Ireland Implanters' registry. Catheterization and Cardiovascular Interventions, 2020, 95, 1340-1346.	1.7	8
21	Initial experience with Impella RP in a quaternary transplant center. Artificial Organs, 2020, 44, 473-477.	1.9	13
22	Surgical explant of a right ventricular assist device with sternum-sparing technique. European Journal of Cardio-thoracic Surgery, 2020, 58, 193-195.	1.4	1
23	Thrombosis Risk with Transcatheter Aortic Valve Replacement. Structural Heart, 2020, 4, 349-359.	0.6	0
24	Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. Lancet, The, 2020, 396, 623-634.	13.7	65
25	The missing acute coronary syndromes in the COVID-19 era. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472097773.	2.1	6
26	Comparison of the self-expanding Evolut-PRO transcatheter aortic valve to its predecessor Evolut-R in the real world multicenter ATLAS registry. International Journal of Cardiology, 2020, 310, 120-125.	1.7	23
27	Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (The NIHR) Tj ETQq1 1 e013684.	l 0.784314 3.7	rgBT /Overlo 16
28	Impella in Cardiogenic Shock: Who and When?. Cardiovascular Revascularization Medicine, 2020, 21, 697.	0.8	1
29	Ten-year improved survival in patients with multi-vessel coronary disease and poor left ventricular function following surgery: A retrospective cohort study. International Journal of Surgery, 2020, 76, 146-152.	2.7	2
30	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. Expert Review of Clinical Pharmacology, 2020, 13, 605-613.	3.1	5
31	Subclavian Impella 5.0 to the rescue in a non-ST elevation myocardial infarction patient requiring unprotected left main rotablation: A case report. World Journal of Cardiology, 2020, 12, 155-160.	1.5	0
32	Left ventricular speckle tracking echocardiographic evaluation before and after TAVI. Echo Research and Practice, 2020, 7, 29-38.	2.5	4
33	Inconsistency in aortic stenosis severity between CT and echocardiography: prevalence and insights into mechanistic differences using computational fluid dynamics. Open Heart, 2019, 6, e001044.	2.3	6
34	Percutaneous Impella CP exchange with preservation of transfemoral access. Cardiovascular Revascularization Medicine, 2019, 20, 63-66.	0.8	0
35	Combined Use of Left Ventricular Assist Device, Extra Corporeal Life Support and Impella RP. Cardiovascular Revascularization Medicine, 2019, 20, 67-69.	0.8	2
36	Coronary artery bypass confers intermediate-term survival benefit over percutaneous coronary intervention with new-generation stents in real-world patients with multivessel coronary artery disease, including left main disease: a retrospective analysis of 6383 patients. European Journal of Cardio-thoracic Surgery, 2019, 56, 911-918.	1.4	8

#	Article	IF	CITATIONS
37	Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres. BMJ, The, 2019, 367, l6055.	6.0	45
38	Initial experience of a large, selfâ€expanding, and fully recapturable transcatheter aortic valve: The UK & Ireland Implanters' registry. Catheterization and Cardiovascular Interventions, 2019, 93, 751-757.	1.7	13
39	Realâ€world comparison of the new 34 mm selfâ€expandable transcatheter aortic prosthesis Evolut R to its 31 mm core valve predecessor. Catheterization and Cardiovascular Interventions, 2019, 93, 685-691.	1.7	6
40	How to save a life: the multidevice patient. European Heart Journal, 2019, 40, 677-677.	2.2	2
41	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
42	The prognostic significance of incomplete revascularization and untreated coronary anatomy following percutaneous coronary intervention: An analysis of 6,755 patients with multivessel disease. Catheterization and Cardiovascular Interventions, 2018, 91, 1229-1239.	1.7	6
43	Pocket-Size Hand-Held Echocardiography. , 2018, , 937-943.		1
44	Six-Month Follow-up Images of 3D Transesophageal Echocardiography and Computed Tomography After SAPIEN3 Implantation in the Descending Aorta. Canadian Journal of Cardiology, 2018, 34, 1233.e17-1233.e19.	1.7	0
45	Effect of Aortic Valve Calcium Quantity on Outcome After Balloon Aortic Valvuloplasty for Severe Aortic Stenosis. American Journal of Cardiology, 2018, 122, 1036-1041.	1.6	Ο
46	Association between fractional flow reserve, instantaneous wave-free ratio and dobutamine stress echocardiography in patients with stable coronary artery disease. EuroIntervention, 2018, 13, 1959-1966.	3.2	6
47	Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction. International Journal of Cardiovascular Imaging, 2017, 33, 687-698.	1.5	16
48	Echocardiographic assessment in patients with chronic kidney disease: Current update. Echocardiography, 2017, 34, 594-602.	0.9	12
49	Genetic variations in the alanine–glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis. Amino Acids, 2017, 49, 1133-1141.	2.7	4
50	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. International Journal of Cardiology, 2017, 246, 26-31.	1.7	7
51	Adenosine induced ventricular fibrillation in a structurally normal heart: a case report. Journal of Medical Case Reports, 2017, 11, 21.	0.8	9
52	Longitudinal deformation of a third generation zotarolimus eluting stent: "The concertina returns!― World Journal of Cardiology, 2017, 9, 60.	1.5	2
53	Sudden cardiac death in patients with rheumatoid arthritis. World Journal of Cardiology, 2017, 9, 562.	1.5	29
54	Bioresorbable scaffolds and drug-eluting balloons for the management of spontaneous coronary artery dissections. Journal of Thoracic Disease, 2016, 8, E1328-E1330.	1.4	11

#	Article	IF	CITATIONS
55	Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. Heart, 2016, 102, 1797-1804.	2.9	52
56	Predictors of Clinical Outcomes in Patients With Stable Coronary Artery Disease. Response. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 1233-1234.	0.6	0
57	A Tricky Percutaneous Paravalvular Leak Closure Two Years After Implantation of 3f Enable Sutureless Bioprosthetic Aortic Valve. Hellenic Journal of Cardiology, 2016, 57, 41-44.	1.0	1
58	Which child catheter should we choose to deliver a bulky bioresorbable vascular scaffold?. International Journal of Cardiology, 2016, 203, 781-782.	1.7	4
59	Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 1135-1143.	0.6	8
60	Transcatheter aortic valve implantation in the young. International Journal of Cardiology, 2016, 203, 626-628.	1.7	1
61	Transarterial Endoleak Closure After Endovascular Thoracoabdominal Aneurysm Repair. Journal of Endovascular Therapy, 2016, 23, 220-224.	1.5	0
62	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. EuroIntervention, 2016, 11, 1355-1362.	3.2	23
63	Impact of clinical and procedural factors upon C reactive protein dynamics following transcatheter aortic valve implantation. World Journal of Cardiology, 2016, 8, 425.	1.5	9
64	Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy. Journal of Heart Valve Disease, 2016, 25, 211-213.	0.5	6
65	Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?. Interventional Cardiology, 2015, 7, 35-54.	0.0	2
66	Left ventricular twist mechanics and its relation with aortic stiffness in chronic kidney disease patients without overt cardiovascular disease. Cardiovascular Ultrasound, 2015, 14, 10.	1.6	7
67	First generation versus new generation drugâ€eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and Newâ€ſokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2015, 85, E63-9.	1.7	8
68	Clinical outcomes of realâ€world patients treated with an amphilimus polymerâ€free stent versus new generation everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
69	Early Outcomes With Direct Flow Medical Versus Firstâ€Generation Transcatheter Aortic Valve Devices: A Singleâ€Center Propensityâ€Matched Analysis. Journal of Interventional Cardiology, 2015, 28, 583-593.	1.2	10
70	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Medical Devices: Evidence and Research, 2015, 8, 317.	0.8	5
71	1-Year Follow-Up Optical Coherence Tomography of a "Hybrid―Neocarina After T-Stenting With Small Protrusion Technique Using a Bioresorbable Vascular Scaffold and a Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, e101-e103.	2.9	2
72	Impact of Strut Width in Periprocedural Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 900-909.	2.9	44

#	Article	IF	CITATIONS
73	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	1.7	34
74	Hybrid Coronary Revascularization. Journal of the American College of Cardiology, 2015, 65, 85-97.	2.8	63
75	A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. International Journal of Cardiology, 2015, 184, 17-21.	1.7	51
76	Side Branch Occlusion After Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2015, 8, 116-118.	2.9	7
77	Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease. European Heart Journal Cardiovascular Imaging, 2015, 16, 539-548.	1.2	38
78	Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents. Canadian Journal of Cardiology, 2015, 31, 328-334.	1.7	22
79	Transcatheter aortic valve implantation with a Direct Flow Medical valve in a patient with severe aortic regurgitation due to degenerated aortic stentless bioprosthesis. International Journal of Cardiology, 2015, 182, 267-270.	1.7	1
80	Diagnostic Coronary Angiography IsÂGetting Old!. JACC: Cardiovascular Imaging, 2015, 8, 11-13.	5.3	6
81	Association Between Corrected QT Interval and Inflammatory Cytokines in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 421-428.	2.0	52
82	In-Scaffold Restenosis in a Previous Left Main Bifurcation Lesion Treated With Bioresorbable Scaffold V-Stenting. JACC: Cardiovascular Interventions, 2015, 8, e7-e10.	2.9	3
83	Two-Year Follow-Up OCT Images of 2ÂBifurcation Lesions Treated With Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Imaging, 2015, 8, 617-618.	5.3	2
84	Acute heart failure management in a young patient requiring complex left main percutaneous coronary intervention, Impella 2.5 and transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 180, 199-202.	1.7	1
85	Simplifying the double kissing (DK) crush with the use of bioresorbable scaffolds. International Journal of Cardiology, 2015, 196, 139-142.	1.7	Ο
86	Clinical Differentiation Between Physiological Remodeling and Arrhythmogenic Right Ventricular Cardiomyopathy in Athletes With Marked Electrocardiographic Repolarization Anomalies. Journal of the American College of Cardiology, 2015, 65, 2702-2711.	2.8	98
87	Clinical Profile of Athletes With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2015, 8, e003454.	2.6	112
88	Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002025.	3.9	80
89	Percutaneous Treatment of a Giant Right Coronary Artery Aneurysm. JACC: Cardiovascular Interventions, 2015, 8, e65-e68.	2.9	2
90	Influence of baseline ejection fraction on the prognostic value of paravalvular leak after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 190, 277-281.	1.7	12

#	Article	IF	CITATIONS
91	Treatment and Clinical Outcomes of Transcatheter Heart Valve Thrombosis. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	244
92	Echocardiographic vs Invasive Measurement of the Direct Flow Transcatheter Aortic Heart Valve Mean Gradient: Contradictory or Complementary?. Canadian Journal of Cardiology, 2015, 31, 1303.e1-1303.e4.	1.7	7
93	Tackling the bends in transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 201, 55-57.	1.7	0
94	Preliminary outcomes after transcatheter aortic valve implantation in patients with systemic sclerosis. EuroIntervention, 2015, 10, 1464-1467.	3.2	8
95	A case of an occlusive right coronary artery dissection after stent implantation: dilemmas and challenges. Journal of Invasive Cardiology, 2015, 27, E13-5.	0.4	1
96	Outcomes in coronary stent trials—1 year is not enough. Nature Reviews Cardiology, 2014, 11, 318-320.	13.7	0
97	Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience. European Heart Journal Cardiovascular Imaging, 2014, 15, 1161-1167.	1.2	62
98	Unanticipated Pseudocoarctation Highlights the Importance of Visualizing Aortic Arch Anatomy Before Transfemoral Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2014, 7, 631-633.	3.9	2
99	A case of Kawasaki's disease with extensive calcifications needing rotational atherectomy with a 2.5mm burr. Cardiovascular Revascularization Medicine, 2014, 15, 248-251.	0.8	3
100	Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations. International Journal of Cardiology, 2014, 175, e11-e13.	1.7	10
101	Prevalence of Electrocardiographic Anomalies in Young Individuals. Journal of the American College of Cardiology, 2014, 63, 2028-2034.	2.8	57
102	Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. International Journal of Cardiology, 2014, 173, 513-514.	1.7	32
103	Hybrid percutaneous coronary revascularisation for a patient with left main bifurcation and extensive, diffuse coronary artery disease. International Journal of Cardiology, 2014, 173, e20-e22.	1.7	3
104	No more metallic cages: An attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel. International Journal of Cardiology, 2014, 172, 618-619.	1.7	9
105	Is "the bigger the better―still valid for drugâ€eluting stents?. Catheterization and Cardiovascular Interventions, 2014, 83, 879-880.	1.7	1
106	Short-term outcomes following "full-plastic jacket―everolimus-eluting bioresorbable scaffold implantation. International Journal of Cardiology, 2014, 177, 607-609.	1.7	9
107	Optimal Duration of Dual Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: Lessons From Optical Coherence Tomography. Canadian Journal of Cardiology, 2014, 30, 1460.e15-1460.e17.	1.7	10
108	One-Year Follow-Up Optical Coherence Tomography After Implantation of Bioresorbable Vascular Scaffolds for aAChronic Coronary Total Occlusion. JACC: Cardiovascular Interventions, 2014, 7, e157-e159.	2.9	5

#	Article	IF	CITATIONS
109	111â€Investigation of the Validity of Cardiovascular Death Certification Amongst Uk Indian Asians and Europeans. Heart, 2014, 100, A64.1-A64.	2.9	0
110	Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis, 2014, 237, 38-44.	0.8	13
111	Why Do We Need Post-Dilation After Implantation of a Bioresorbable Vascular Scaffold Even for a Soft Lesion?. JACC: Cardiovascular Interventions, 2014, 7, 1070-1072.	2.9	3
112	A Case of True Left Main Bifurcation Treated With Bioresorbable Everolimus-Eluting Stent V-Stenting. JACC: Cardiovascular Interventions, 2014, 7, e103-e104.	2.9	12
113	Tardive Coronary Obstruction By a Native Leaflet After Transcatheter Aortic Valve Replacement in a Patient With Heavily Calcified Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2014, 7, e105-e107.	2.9	6
114	Delayed Disruption of a BioresorbableÂVascular Scaffold. JACC: Cardiovascular Imaging, 2014, 7, 845-847.	5.3	2
115	Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology, 2014, 53, 131-137.	1.9	73
116	The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: Correlation with fractional flow reserve. Cardiovascular Revascularization Medicine, 2014, 15, 3-7.	0.8	19
117	Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. International Journal of Cardiology, 2014, 174, e72-e74.	1.7	9
118	Strategy for optimal side-branch positioning of bioresorbable vascular scaffolds in dedicated 2-stent techniques: Insights from optical coherence tomography. Cardiovascular Revascularization Medicine, 2014, 15, 298-300.	0.8	3
119	Bioresorbable vascular scaffold strut disruption after crossing with an optical coherence tomography imaging catheter. International Journal of Cardiology, 2014, 174, e116-e119.	1.7	7
120	After 3 Decades, at Long Last, a New Device to Deal With Calcific Lesions. JACC: Cardiovascular Interventions, 2014, 7, 519-520.	2.9	10
121	Coronary heart disease in Indian Asians. Global Cardiology Science & Practice, 2014, 2014, 4.	0.4	23
122	The South Asian Genome. PLoS ONE, 2014, 9, e102645.	2.5	43
123	Pocket-size hand-held cardiac ultrasound as an adjunct to clinical examination in the hands of medical students and junior doctors. European Heart Journal Cardiovascular Imaging, 2013, 14, 323-330.	1.2	180
124	latrogenic communications between aortic root and right ventricle/left atrium after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2013, 82, E603-8.	1.7	3
125	Target organ damage in patients with rheumatoid arthritis: The role of blood pressure and heart rate. Atherosclerosis, 2010, 209, 255-260.	0.8	30
126	Atherosclerosis in Rheumatoid Arthritis Versus Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1702-1708.	2.4	166

#	Article	IF	CITATIONS
127	Lack of an Association of GNB3 C825T Polymorphism and Blood Pressure in Patients with Rheumatoid Arthritis. Clinical and Experimental Hypertension, 2009, 31, 428-439.	1.3	3
128	Galectin-2 <i>(LGALS2)</i> 3279C/T Polymorphism may be Independently Associated with Diastolic Blood Pressure in Patients with Rheumatoid Arthritis. Clinical and Experimental Hypertension, 2009, 31, 93-104.	1.3	23
129	Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: The role of obesity and smoking. Atherosclerosis, 2009, 204, 178-183.	0.8	85
130	Polymorphisms of the Endothelin-1 Gene Associate with Hypertension in Patients with Rheumatoid Arthritis. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 203-212.	1.7	53